Skip to content
Participate in our active studiesSubscribe to our Mailing List
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
AB ScienceAB Science
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact
  • French
  • English
Search:
  • Home
  • Company
    • Corporate Overview
    • Executive Commitee
    • Scientific Committee
    • Values
  • Science
    • Overview
    • Masitinib in neurodegenerative disorders
    • Masitinib in inflammatory diseases
    • Masitinib in oncology
    • Masitinib in viral diseases
    • AB8939 in oncology
    • Publications
  • Pipeline
    • Pipeline Overview
    • Masitinib
      • Multiple Sclerosis
      • Amyotrophic Lateral Sclerosis
      • Alzheimer’s Disease
      • Indolent Systemic Mastocytosis
      • Mast Cell Activation Syndrome
      • Severe Asthma
      • Prostate Cancer
      • Pancreatic Cancer
      • COVID-19
    • AB8939
  • News and Media
    • Press releases
    • In the Media
    • Webcasts
  • Investors
    • Why invest in AB Science
    • Investor Kit
    • Regulated information
      • Annual reports
      • Half-year reports
      • Social and environmental responsabilities
      • Shareholders General Meeting
      • Outstanding shares and voting rights
      • Regulated agreements
      • Board of Directors Charter
    • Stock Information
      • General Information
      • Analyst Coverage
    • Financial Calendar
    • Events
  • Masivet®
    • About Masivet®
    • Medical information and Pharmacovigilance
  • Careers
  • Contact

Tag Archives: 2019

You are here:
  1. Home
  2. Entries tagged with "2019"

June 4 2019 web conference presentation

2019By Alexis BERNARDJune 4, 2019

04/06/2019 – AB Science web conference presentation (Part 1)

Web conference on June 4 and 5, 2019

2019By Alexis BERNARDMay 30, 2019

30/05/2019 – AB Science will hold a web conference on its outlook for 2019 on June 4 and 5, 2019 from 5.30 pm to 7pm CET

Lifting of the ANSM clinical hold

2019By Alexis BERNARDMay 28, 2019

28/05/2019 – AB Science announces the lifting of the ANSM clinical hold.

Annual financial results as of 31 December, 2018

2019By Alexis BERNARDApril 30, 2019

30/04/2019 – AB Science reports its annual financial results as of 31 December 2018.

Presentation of new masitinib preclinical data in ALS at the 2019 Muscular Dystrophy Association Conference

2019By Alexis BERNARDApril 16, 2019

16/04/2019- AB Science presented new preclinical data for masitinib in ALS at the 2019 Muscular Dystrophy Association Conference.

Acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference

2019By Alexis BERNARDMarch 21, 2019

21/03/2019 – AB Science announces acceptance of abstract for oral presentation at the 2019 Muscular Dystrophy Association Conference.

←12345←
AB Science
© AB Science – All right reserved
Go to Top